D
Crinetics Pharmaceuticals, Inc. CRNX
$46.98 $1.974.38% NASDAQ
Recommendation
Prev Close
$45.01
Volume
1,154,339
Avg Vol (90D)
1,457,845
Market Cap
$4.27B
Dividend & Yield
--
52-Week Range
$24.10 - $60.34
P/E (TTM)
--
EPS (TTM)
-$4.53
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Assessing Crinetics Pharmaceuticals Valuation After Stock Volatility and Pipeline Progress in 2025
12/3/2025 - Simply Wall St
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
12/3/2025 - Globe Newswire
XTX Topco Ltd Acquires Shares of 34,013 Crinetics Pharmaceuticals, Inc. $CRNX
12/2/2025 - MarketBeat
Prudential Financial Inc. Has $4.69 Million Position in Crinetics Pharmaceuticals, Inc. $CRNX
12/2/2025 - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of "Moderate Buy" by Brokerages
12/1/2025 - Ticker Report
Crinetics Pharmaceuticals (CRNX): Evaluating Valuation After Pivotal Phase 3 Milestone for Paltusotine in Carcinoid Syndrome
12/1/2025 - Simply Wall St
Franklin Resources Inc. Sells 314,143 Shares of Crinetics Pharmaceuticals, Inc. $CRNX
11/30/2025 - MarketBeat
Why Crinetics Pharmaceuticals (CRNX) Is Up 6.3% After Pivotal Phase 3 Paltusotine Trial Launch
11/29/2025 - Simply Wall St
Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?
11/28/2025 - Zacks Investment Research
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year
11/27/2025 - Fool.com Headlines
Crinetics Pharmaceuticals (CRNX, $46.03) price may drop as it broke higher Bollinger Band on Nov 26, 2025
11/27/2025 - Tickeron - Stocks
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
11/27/2025 - Zacks Investment Research
SG Americas Securities LLC Sells 501,984 Shares of Crinetics Pharmaceuticals, Inc. $CRNX
11/27/2025 - MarketBeat
Crinetics Pharmaceuticals (CRNX, $44.71) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 25, 2025
11/26/2025 - Tickeron - Stocks
Crinetics Pharmaceuticals (CRNX, $44.71) Stochastic Oscillator left the overbought zone on November 25, 2025
11/26/2025 - Tickeron - Stocks
AXQ Capital LP Acquires New Shares in Crinetics Pharmaceuticals, Inc. $CRNX
11/26/2025 - MarketBeat
Segall Bryant & Hamill LLC Buys 30,243 Shares of Crinetics Pharmaceuticals, Inc. $CRNX
11/25/2025 - MarketBeat
Ensign Peak Advisors Inc Sells 199,245 Shares of Crinetics Pharmaceuticals, Inc. $CRNX
11/24/2025 - MarketBeat
Geode Capital Management LLC Raises Stake in Crinetics Pharmaceuticals, Inc. $CRNX
11/24/2025 - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts
11/24/2025 - MarketBeat
Crinetics Pharmaceuticals (CRNX): Valuation in Focus After Key Phase 3 Paltusotine Trial Milestone
11/24/2025 - Simply Wall St
Crinetics Pharmaceuticals (CRNX, $42.86) entered Uptrend as Momentum indicator ascends above 0 level on Nov 21, 2025
11/22/2025 - Tickeron - Stocks
Will the CAREFNDR Phase 3 Launch Broaden Crinetics Pharmaceuticals' (CRNX) Long-Term Growth Narrative?
11/22/2025 - Simply Wall St
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
11/20/2025 - Globe Newswire
Crinetics Pharmaceuticals (CRNX, $43.01) Stochastic Oscillator left the overbought zone on November 18, 2025
11/19/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
$1.54M
EBITDA (TTM)
-$474.16M
EBIT (TTM)
-$477.85M
Net Income (TTM)
-$423.10M
Balance Sheet
Total Assets (Q)
$1.20B
Total Debt (Q)
$49.14M
Total Liabilities (Q)
$123.86M
Book Value Per Share (Q)
$11.34
Cash Flow
Cash from Operations (TTM)
-$349.70M
Cash from Investing (TTM)
-$425.29M
Cash from Financing (TTM)
$568.61M
Net Change in Cash (TTM)
-$206.37M
Filings
Filing Date
Thursday, November 6, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
1.36
7-Day Total Return
9.61%
30-Day Total Return
9.64%
60-Day Total Return
28.71%
90-Day Total Return
55.05%
Year to Date Total Return
-8.87%
1-Year Total Return
-16.98%
2-Year Total Return
40.66%
3-Year Total Return
156.44%
5-Year Total Return
260.28%
52-week Low
Apr 09, 2025 - $24.10
52-week High
Dec 11, 2024 - $60.34
Valuation
Market Cap
$4.27B - Mid Cap
Enterprise Value
$3.23B
Price/Sales (TTM)
2,778.40
Price/Book (Q)
3.97
Dividends and Shares
Shares Outstanding
94.22
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.crinetics.com
Phone Number
858 450 6464
Address
6055 Lusk Boulevard
San Diego, CA 92121
Country
United States
Year Founded
2008
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and... more
NASDAQ 12/03/2025 4:00PM Eastern Quotes delayed